Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$3.19 USD

3.19
2,265,425

+0.23 (7.77%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $3.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Editas Medicine (EDIT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.

Glaxo Inks Genome Research Deal With University of California

Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.

CRISPR Therapeutics Up on Collaboration Expansion by Vertex

CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.

Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.

Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil

Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.

IVERIC bio's (ISEE) Q1 Loss Narrows, Gene Therapy in Focus

IVERIC bio (ISEE) first-quarter earnings beat estimates. The company is focusing on developing gene therapies for treating inherited retinal diseases.

Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -5.26% and -73.30%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.

Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?

Is (EDIT) Outperforming Other Medical Stocks This Year?

Is a Beat in Store for Editas (EDIT) This Earnings Season?

On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.

Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Should You Buy?

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.

Editas (EDIT) Inks Cross Licensing Agreement with BlueRock

Editas (EDIT) inks a research and cross licensing agreement with BlueRock Therapeutics, LP.

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

Editas (EDIT) to Report Q4 Earnings: What's in the Cards?

Focus of Editas' (EDIT) fourth-quarter conference call is likely to be on its pipeline.

CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study

CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.

Tirthankar Chakraborty headshot

5 Gene Therapy Stocks to Enrich Your Portfolio

Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.

Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know

Editas Medicine (EDIT) closed the most recent trading day at $19.86, moving -0.45% from the previous trading session.

Editas Medicine (EDIT) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $19.75, marking a +1.65% move from the previous day.

Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $21.60, marking a -0.6% move from the previous day.

Editas Medicine (EDIT) Gains But Lags Market: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $21.46, marking a +0.61% move from the previous day.

Editas Medicine (EDIT) Stock Sinks As Market Gains: What You Should Know

Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.

Editas Medicine (EDIT) Dips More Than Broader Markets: What You Should Know

Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.